Amedisys Inc Stock Research

Market Summary

USD77.31+0.56

Delayed

0.73%

AMED Stock Price

AMED RSI Chart

AMED Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

22.43

Price/Sales (Trailing)

1.13

EV/EBITDA

14.07

Price/Free Cashflow

24.19

AMED Price/Sales (Trailing)

AMED Profitability

EBT Margin

7.21%

Return on Equity

11.28%

Return on Assets

Free Cashflow Yield

4.13%

AMED Fundamentals

AMED Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

2.04%

Revenue Q/Q

-1.01%

AMED Earnings

Earnings (TTM)

112.2M

Earnings Y/Y

-20.29%

Earnings Q/Q

-20.4%

Price Action

52 Week Range

69.45131.32

(Low)(High)

Last 7 days

-2.6%

Last 30 days

0.9%

Last 90 days

-15.8%

Trailing 12 Months

-34.1%

AMED Financial Health

Current Ratio

1.09

Debt/Equity

0.4

Debt/Cashflow

0.32

AMED Investor Care

Buy Backs (1Y)

0.07%

Diluted EPS (TTM)

3.44

Peers (Alternatives to Amedisys)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
HCA	73.0B	60.9B	-4.91%	25.24%	12.73	1.2	1.94%	-15.77%
LH	20.7B	14.8B	-2.77%	-13.32%	16.22	1.39	-6.96%	-52.35%
DGX	15.0B	9.6B	-8.90%	-4.59%	18.89	1.56	-10.08%	-57.84%
MID-CAP
UHS	9.9B	13.6B	-10.37%	3.84%	14.64	0.74	5.04%	-26.87%
CHE	8.1B	2.2B	-3.35%	8.33%	33.85	3.75	1.03%	-10.38%
LHCG	5.2B	2.3B	3.17%	35.63%	86.23	2.28	2.85%	-58.05%
ENSG	5.0B	3.2B	-11.17%	9.89%	21.14	1.55	17.88%	19.62%
AMN	3.9B	4.8B	11.84%	2.65%	10.12	0.8	3.57%	-4.88%
GH	2.9B	482.2M	34.10%	-27.10%	-4.41	5.98	23.29%	-70.12%
AMED	2.5B	2.2B	0.86%	-34.14%	22.43	1.13	0.55%	-41.23%
SMALL-CAP
RDNT	1.7B	1.5B	6.01%	44.82%	-126.07	1.14	10.24%	-173.11%
ADUS	1.4B	976.1M	-21.09%	3.91%	28.65	1.47	10.19%	12.37%
NHC	919.4M	1.1B	3.90%	-11.21%	51.63	0.85	-2.36%	-86.62%
VMD	394.4M	146.1M	-12.69%	63.35%	63.38	2.84	20.87%	-35.06%

Financials for Amedisys

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	0.5%	2,234	2,223	2,220	2,216	2,222
S&GA Expenses	1.7%	736	724	-	-	-
Costs and Expenses	0.8%	2,059	2,042	2,038	2,015	1,996
EBITDA	-3.0%	207	214	235	298	-
EBITDA Margin	-3.1%	0.09*	0.10*	0.11*	0.13*	-
Earnings Before Taxes	-5.6%	151	160	166	187	256
EBT Margin	-3.5%	0.07*	0.07*	0.08*	0.12*	-
Interest Expenses	19.5%	27.00	22.00	19.00	17.00	11.00
Net Income	-5.4%	112	119	121	140	191
Net Income Margin	-2.0%	0.05*	0.05*	0.06*	0.09*	-
Free Cahsflow	38.0%	127	92.00	167	178	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-1.5%	1,947	1,976	1,982	2,001	1,908
Current Assets	4.3%	406	389	389	395	392
Cash Equivalents	70.4%	69.00	41.00	18.00	27.00	68.00
Net PPE	108.5%	33.00	16.00	17.00	18.00	17.00
Goodwill	-3.3%	1,245	1,287	1,285	1,290	9.00
Liabilities	-6.4%	814	870	913	962	888
Current Liabilities	-0.7%	353	356	367	427	380
Long Term Debt	-11.0%	373	419	443	442	429
Shareholder's Equity	7.8%	1,133	1,052	1,016	1,039	1,021
Retained Earnings	3.3%	783	758	726	700	671
Additional Paid-In Capital	0.5%	759	755	751	743	737
Accumulated Depreciation	3.7%	105	101	102	100	99.00
Shares Outstanding	0.1%	33.00	33.00	32.00	32.00	33.00
Minority Interest	-1.4%	54.00	55.00	54.00	53.00	54.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-17.0%	111	133	98.00	173	184
Share Based Compensation	-24.6%	12.00	17.00	22.00	23.00	24.00
Cashflow From Investing	65.6%	-32.51	-94.49	-104	-367	-296
Cashflow From Financing	-162.6%	-79.92	-30.43	-90.03	151	105
Buy Backs	-46.4%	17.00	32.00	43.00	27.00	-

Risks for AMED

What is the probability of a big loss on AMED?

73.1%

Probability that Amedisys stock will be more than 20% underwater in next one year

36.5%

Probability that Amedisys stock will be more than 30% underwater in next one year.

33.5%

Probability that Amedisys stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AMED drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Amedisys was unfortunately bought at previous high price.

Drawdowns

Returns for AMED

Cumulative Returns on AMED

19.7%

10-Year Cumulative Returns

6.2%

7-Year Cumulative Returns

0.7%

5-Year Cumulative Returns

-25.7%

3-Year Cumulative Returns

What are the long-term rolling returns for AMED?

FIve years rolling returns for Amedisys.

Annualized Returns

Which funds bought or sold AMED recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-23	Capital Impact Advisors, LLC	reduced	-33.37	-233,989	332,078	0.41%
2023-05-23	Front Row Advisors LLC	unchanged	-	-	2,000	-%
2023-05-23	Seaport Global Advisors, LLC	added	12.37	-2,017	186,449	0.59%
2023-05-23	Toroso Investments, LLC	new	-	478,000	478,000	0.01%
2023-05-22	FDx Advisors, Inc.	unchanged	-	-	231,000	0.01%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-24.99	-30,716,200	59,729,800	0.02%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	added	8.57	-181,000	3,918,000	-%
2023-05-18	JPMORGAN CHASE & CO	added	13.48	-139,000	146,881,000	0.02%
2023-05-17	Sunbelt Securities, Inc.	new	-	5,823	5,823	-%
2023-05-17	Advisory Services Network, LLC	unchanged	-	-7,702	56,708	-%

Latest Funds Activity

Are funds buying AMED calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own AMED

No. of Funds

Amedisys News

Schedule 13G FIlings of Amedisys

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 18, 2023	flynn james e	5.51%	1,794,000	SC 13G
Feb 14, 2023	ameriprise financial inc	3.39%	1,100,719	SC 13G/A
Feb 09, 2023	vanguard group inc	9.63%	3,128,416	SC 13G/A
Feb 06, 2023	wellington management group llp	8.63%	2,802,831	SC 13G/A
Jan 26, 2023	blackrock inc.	12.6%	4,106,566	SC 13G/A
Jan 20, 2023	blackrock inc.	12.6%	4,106,566	SC 13G
Jan 06, 2023	jpmorgan chase & co	5.4%	1,763,327	SC 13G
Feb 14, 2022	ameriprise financial inc	5.35%	1,742,916	SC 13G
Feb 09, 2022	vanguard group inc	9.69%	3,158,777	SC 13G/A
Feb 04, 2022	wellington management group llp	5.56%	1,812,411	SC 13G/A

AMED Fair Value

Amedisys fair value in different scenarios

The table shows the Fair Value estimates for Amedisys for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	57.59 -25.51%	70.52 -8.78%	90.91 17.59%	121.81 57.56%	139.69 80.69%
Current Inflation	53.76 -30.46%	64.93 -16.01%	82.14 6.25%	108.07 39.79%	123.02 59.13%
Very High Inflation	48.98 -36.64%	58.09 -24.86%	71.66 -7.31%	92.01 19.01%	103.69 34.12%

Historical Amedisys Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Amedisys

View All Filings

Date Filed	Form Type	Document
May 26, 2023	425	Prospectus Filed
May 26, 2023	425	Prospectus Filed
May 18, 2023	425	Prospectus Filed
May 18, 2023	SC 13G	Major Ownership Report
May 17, 2023	425	Prospectus Filed
May 15, 2023	425	Prospectus Filed
May 15, 2023	425	Prospectus Filed
May 15, 2023	425	Prospectus Filed
May 15, 2023	425	Prospectus Filed
May 10, 2023	425	Prospectus Filed

Latest Insider Trading transactions for AMED

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-03	Samuels Ivanetta Davis	acquired	-	-	1,941	-
2023-05-03	Klapstein Julie D	acquired	-	-	1,941	-
2023-05-03	PERKINS BRUCE D	acquired	-	-	1,941	-
2023-05-03	Rideout Jeffrey A	acquired	-	-	1,941	-
2023-05-03	CAPPS VICKIE L	acquired	-	-	1,941	-
2023-05-03	Coye Molly Joel	acquired	-	-	1,941	-
2023-05-03	Kline Teresa L.	acquired	-	-	1,941	-
2023-04-12	Ashworth Richard M	acquired	-	-	46,982	president and ceo
2023-04-10	Kusserow Paul B. K.	sold (taxes)	-1,282,350	78.88	-16,257	-
2023-03-03	North Michael Paul	sold	-510,628	86.43	-5,908	chief information officer

About Amedisys

Christopher T. Gerard

www.amedisys.com

21000

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Income Statement

2023-03-31

CONSOLIDATED INCOME STATEMENT - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net service revenue	$ 556,389	$ 545,257
Cost of service, inclusive of depreciation	315,010	304,820
General and administrative expenses:
Salaries and benefits	126,339	123,480
Non-cash compensation	3,273	7,347
Depreciation and amortization	4,443	8,008
Other	64,945	53,640
Total operating expenses	514,010	497,295
Operating income	42,379	47,962
Other income (expense):
Interest income	406	13
Interest expense	(7,517)	(3,173)
Equity in earnings (loss) from equity method investments	123	(1,403)
Miscellaneous, net	(682)	333
Total other expense, net	(7,670)	(4,230)
Income before income taxes	34,709	43,732
Income tax expense	(9,800)	(12,019)
Net income	24,909	31,713
Net loss (income) attributable to noncontrolling interests	337	(42)
Net income attributable to Amedisys, Inc.	$ 25,246	$ 31,671
Basic earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)	$ 0.78	$ 0.97
Weighted average shares outstanding, basic (shares)	32,558	32,555
Diluted earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)	$ 0.77	$ 0.97
Weighted average shares outstanding, diluted (shares)	32,643	32,766

AMED Balance Sheet

2023-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 49,436	$ 40,540
Restricted cash	19,664	13,593
Patient accounts receivable	294,122	296,785
Prepaid expenses	18,754	11,628
Other current assets	23,581	26,415
Total current assets	405,557	388,961
Property and equipment, net of accumulated depreciation of $105,183 and $101,364	33,353	16,026
Operating lease right of use assets	85,211	102,856
Goodwill	1,244,679	1,287,399
Intangible assets, net of accumulated amortization of $16,071 and $14,604	99,929	101,167
Other assets	78,230	79,836
Total assets	1,946,959	1,976,245
Current liabilities:
Accounts payable	40,017	43,735
Payroll and employee benefits	122,723	125,387
Accrued expenses	137,899	137,390
Current portion of long-term obligations	26,958	15,496
Current portion of operating lease liabilities	25,453	33,521
Total current liabilities	353,050	355,529
Long-term obligations, less current portion	373,202	419,420
Operating lease liabilities, less current portion	59,826	69,504
Deferred income tax liabilities	22,752	20,411
Other long-term obligations	4,781	4,808
Total liabilities	813,611	869,672
Commitments and Contingencies—Note 7
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding	0	0
Common stock, $0.001 par value, 60,000,000 shares authorized; 37,938,354 and 37,891,186 shares issued; 32,544,145 and 32,511,465 shares outstanding	38	38
Additional paid-in capital	758,669	755,063
Treasury stock, at cost, 5,394,209 and 5,379,721 shares of common stock	(462,508)	(461,200)
Retained earnings	782,918	757,672
Total Amedisys, Inc. stockholders’ equity	1,079,117	1,051,573
Noncontrolling interests	54,231	55,000
Total equity	1,133,348	1,106,573
Total liabilities and equity	$ 1,946,959	$ 1,976,245